


CORRECTION

Open Access



# Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

Edith A. Perez<sup>1\*</sup> , Sanne Lysbet de Haas<sup>2</sup>, Wolfgang Eiermann<sup>3</sup>, Carlos H. Barrios<sup>4</sup>, Masakazu Toi<sup>5</sup>, Young-Hyuck Im<sup>6</sup>, Pier Franco Conte<sup>7</sup>, Miguel Martin<sup>8</sup>, Tadeusz Pienkowski<sup>9</sup>, Xavier B. Pivot<sup>10</sup>, Howard A. Burris III<sup>11</sup>, Sven Stanzel<sup>2</sup>, Monika Patre<sup>2</sup> and Paul Anthony Ellis<sup>12</sup>

## Correction to: BMC Cancer

<https://doi.org/10.1186/s12885-019-5687-0>

Following publication of the original article [1], the authors reported the following errors in the article.

- 1) In Table 2, the layout has been updated. The corrected Table 2 is supplied below:
- 2) The legend for Fig. 3 has been adapted for clearer readability. The updated legend is as follows:
- 3) The competing interests statement has been updated below.

## Competing interests

EAP was a salaried employee of Genentech, Inc. at the time this work was prepared and owns stock in F. Hoffmann-La Roche Ltd. SLdH, SS, and MP are salaried employees of F. Hoffmann-La Roche Ltd. SS and MP own stock in F. Hoffmann-La Roche Ltd. WE has served as a consultant and on Speakers' Bureaus for F. Hoffmann-La Roche Ltd. CHB has served as a consultant for F. Hoffmann-La Roche Ltd., Pfizer, GlaxoSmithKline, Novartis, Boehringer Ingelheim, and Eisai and has received research funding from Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, F. Hoffmann-La Roche/Genentech, Eisai, Lilly, Sanofi-Aventis, and Celgene. MT has received research funding from Chugai Pharmaceutical. PFC has served on Speakers' Bureaus for Novartis, F. Hoffmann-La Roche Ltd., and AstraZeneca and has received research funding from F. Hoffmann-La Roche Ltd. and Novartis. MM has received honoraria from and has served as a consultant for F. Hoffmann-La Roche Ltd. TP has received honoraria and research funding from F. Hoffmann-La Roche Ltd., Pfizer, and Novartis. He has also served as a consultant for F. Hoffmann-La Roche Ltd. XBP has received honoraria from F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Amgen, Novartis, Pierre Fabre, and

Eisai. He has also served as a consultant for F. Hoffmann-La Roche Ltd., Amgen, Novartis, Pierre Fabre, and Eisai. Y-HI, HAB, and PAE have nothing to disclose.

## Author details

<sup>1</sup>Mayo Clinic, 4500 San Pablo Rd. S, Jacksonville, FL 32224, USA. <sup>2</sup>F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland. <sup>3</sup>Interdisciplinary Oncology Center, Nussbaumstrasse 12, 80336 Munich, Germany. <sup>4</sup>PUCRS School of Medicine, Av. Ipiranga 6681, Porto Alegre, RS 90619-900, Brazil. <sup>5</sup>Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan. <sup>6</sup>Samsung Medical Centre, 81 Irwon-Ro Gangnam-gu, Seoul 06351, South Korea. <sup>7</sup>Department of Surgery, Oncology and Gastroenterology, University of Padova and Istituto Oncologico Veneto, Via Gattamelata 64, 35128 Padova, Italy. <sup>8</sup>Instituto de Investigacion Sanitaria Gregorio Marañón, CIBERONC, GEICAM, Universidad Complutense, Avda. de Séneca, 2, 28040 Madrid, Spain. <sup>9</sup>Postgraduate Medical Education Center, ul. Marymoncka 99, 02-813 Warsaw, Poland. <sup>10</sup>Paul Strauss Cancer Center, 3 Rue de la Porte de l'Hôpital, BP 30042, 67065 Strasbourg, France. <sup>11</sup>Sarah Cannon Research Institute and Tennessee Oncology, PLLC, 250 25th Ave N, Nashville, TN 37203, USA. <sup>12</sup>Guys Hospital and Sarah Cannon Research Institute, Great Maze Pond, London SE1 9RT, UK.

Received: 13 June 2019 Accepted: 13 June 2019

Published online: 24 June 2019

## Reference

1. Perez, et al. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2- positive advanced breast cancer. *BMC Cancer*. 2019;19:517 <https://doi.org/10.1186/s12885-019-5687-0>.

\* Correspondence: [Perez.edith@mayo.edu](mailto:Perez.edith@mayo.edu)

<sup>1</sup>Mayo Clinic, 4500 San Pablo Rd. S, Jacksonville, FL 32224, USA  
Full list of author information is available at the end of the article



**Table 2** Progression-free survival by HER2 expression subgroups

	Trastuzumab + taxane (Control)		T-DM1 (T-DM1)		HR vs. trastuzumab + taxane (97.5% CI) <sup>a</sup>	T-DM1 + pertuzumab (T-DM1+P)		HR vs. T-DM1 + placebo (97.5% CI) <sup>a</sup>	
	No. patients / No. patients with PFS event	Median PFS (mo)	No. patients / No. patients with PFS event	Median PFS (mo)		No. patients / No. patients with PFS event	Median PFS (mo)		HR vs. trastuzumab + taxane (97.5% CI) <sup>a</sup>
All patients <sup>b</sup>									
IHC 3+	333/209	14.4	340/215	14.6	0.93 (0.75–1.16)	331/195	16.7	0.83 (0.67–1.04)	0.90 (0.72–1.12)
IHC 2+	27/19	12.6	25/20	7.3	1.13 (0.55–2.32)	29/20	8.3	1.25 (0.61–2.59)	0.98 (0.48–2.02)
IHC 2+/3+ patients combined <sup>c</sup>									
Focal IHC 2+/3+ (10–29%) <sup>d</sup>	14/8	12.4	12/10	6.4	1.51 (0.52–4.40)	15/12	7.5	1.41 (0.50–3.94)	1.00 (0.38–2.65)
Heterogeneous IHC 2+/3+ (30–79%)	35/27	10.6	37/25	8.3	1.04 (0.55–1.94)	33/20	6.3	1.11 (0.57–2.17)	0.91 (0.46–1.78)
Homogeneous IHC 2+/3+ (≥80%)	311/193	14.6	316/200	14.7	0.92 (0.74–1.16)	312/183	17.8	0.82 (0.65–1.04)	0.89 (0.71–1.13)
IHC 3+ patients only									
Focal IHC 3+ (10–29%) <sup>d</sup>	9/5	8.3	11/7	8.3	1.20 (0.32–4.50)	8/7	4.2	5.11 (0.99–26.40)	2.28 (0.60–8.71)
Heterogeneous IHC 3+ (30–79%)	44/29	10.5	45/34	10.0	1.15 (0.65–2.03)	29/16	17.8	0.79 (0.39–1.60)	0.65 (0.33–1.29)
Homogeneous IHC 3+ (≥80%)	280/175	14.6	284/174	15.2	0.89 (0.70–1.14)	294/172	17.7	0.82 (0.65–1.05)	0.92 (0.73–1.17)

<sup>a</sup>Unstratified hazard ratio

<sup>b</sup>Five patients with IHC 0/1+ and five patients with unknown IHC status are not included in this table

<sup>c</sup>Categories were based on IHC subgroup and then combined

<sup>d</sup>Compared with the overall population, samples with focal HER2 expression were more likely to express mutated PIK3CA and lower levels of HER2 mRNA  
*CI* confidence interval, *HER2* human epidermal growth factor receptor 2, *HR* hazard ratio, *IHC* immunohistochemistry, *NE* not estimable, *P* pertuzumab, *PFS* progression-free survival, *PIK3CA* phosphoinositide 3-kinase catalytic subunit alpha, *T-DM1* trastuzumab emtansine

